U.S. Food Stock News

Donaldson Company (DCI) just delivered another upside surprise, pairing record quarterly sales and earnings with a guidance bump that signals management sees this momentum carrying into 2026, not just flashing temporarily. See our latest analysis for Donaldson Company. The latest beat and guidance hike build on a strong run, with a roughly 38% year to date share price return and five year total shareholder return of about 77% pointing to steadily building momentum as investors re-rate its...

Wondering if Progress Software is quietly becoming a value opportunity, or a trap that just looks cheap on the surface? This breakdown is designed to give you a clear, no nonsense view of what you are really buying at today’s price. The stock has bounced about 4.1% over the last week and 4.7% over the last month, but it is still down roughly 30.3% year to date and 35.2% over the past year. That tells us sentiment has been weak even as short term buyers start to nibble again. Those moves sit...

BridgeBio Pharma (BBIO) just delivered a quarter where revenue topped expectations, thanks largely to strong U.S. demand for its heart drug Attruby, even as the company remained in the red. See our latest analysis for BridgeBio Pharma. Those upbeat Attruby numbers and the recent insider share sale have landed as the stock keeps grinding higher, with a roughly 11 percent 1 month share price return feeding into a powerful 1 year total shareholder return above 160 percent. This is a sign that...

Avient (AVNT) just doubled down on its long term playbook by cutting costs, raising prices where it can, and closing the DSM protective materials deal that brings the Dyneema brand into its portfolio. See our latest analysis for Avient. The market reaction has been cautious so far, with the share price at $31.51 and a 1 month share price return of 5.7 percent. However, a year to date share price return of negative 21.7 percent and a 1 year total shareholder return of negative 32.4 percent...

Many investors are asking whether Carlyle Group at around $60 is still a smart buy or if most of the upside is already reflected in the price, and that is exactly what we are going to unpack here. The stock has climbed 6.9% over the last week, 11.7% over the past month, and is now up 18.6% year to date, adding to an increase of 123.1% over three years and 126.2% over five years. Recent headlines have focused on Carlyle sharpening its emphasis on core private equity, credit, and...

Chewy (CHWY) just posted its Q3 2026 numbers, with revenue of about $3.1 billion and net income of $59.2 million translating into basic EPS of roughly $0.14 as investors parse how the pet retailer is holding up in a tougher consumer backdrop. The company has seen quarterly revenue move from $2.88 billion in Q3 2025 to around $3.1 billion across 2026 so far, while basic EPS shifted from $0.01 a year ago to roughly the mid-$0.14 range in each quarter, setting up this print as a test of how...

In early December 2025, WisdomTree, Inc. launched the WisdomTree Equity Premium Income Digital Fund, a tokenized product tracking the Volos U.S. Large Cap Target 2.5% PutWrite Index and available via its WisdomTree Prime and WisdomTree Connect platforms. This launch comes as WisdomTree reports record assets under management of US$139.00 billion and strong net inflows, underscoring its push to blend income-focused equity strategies with blockchain-based fund structures. We’ll now examine how...

If you are wondering whether Atlassian is a bargain or a value trap at today’s price, you are not alone. This breakdown is designed to help you decide with greater confidence. The stock has bounced about 4.3% over the last week and 3.6% in the past month, but it is still down roughly 32.6% year to date and 41.5% over the last year. That combination often signals either deep value or lingering risk. Those moves have come as investors weigh Atlassian’s ongoing push to scale its cloud platform...

While Groupon, Inc. ( NASDAQ:GRPN ) shareholders are probably generally happy, the stock hasn't had particularly good...

Over the past year, insiders sold US$424k worth of Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) stock at an average...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Patrick Industries recently appeared in Mairs & Power Small Cap Fund’s third-quarter 2025 investor letter as a new holding, and earlier this month presented at the Raymond James TMT & Consumer Conference in New York, underscoring its profile across recreational vehicle, marine, manufactured housing, and residential construction markets. The fund’s decision to initiate a position after tariff and inventory concerns had pressured the stock highlights how some institutional investors view...

ICF International (ICFI) has been grinding through a mixed stretch in the market, and that uneven share performance is nudging investors to revisit whether the current valuation still makes sense. See our latest analysis for ICF International. Over the past few months, ICF International’s share price has tried to claw back ground, with a 1 month share price return of 11.12 percent partially offsetting a weaker year to date share price return of 24.44 percent and a 1 year total shareholder...

If you have been wondering whether Celanese is a beaten down bargain or a value trap, this is exactly the kind of setup where a deeper valuation check can make a real difference to your returns. The stock has bounced 7.4% over the last week and 3.4% over the last month, but that is off a much lower base after a painful slide of around 37.5% year to date and 37.7% over the last year. Investors have been digesting a mix of macro headlines around demand for specialty materials and chemicals,...

Proto Labs (PRLB) has quietly put together a strong run this year, with the stock up about 37% year to date and roughly 20% over the past year, outpacing many industrial peers. See our latest analysis for Proto Labs. That momentum has not come out of nowhere, with a 7.5% 1 month share price return and a 20.2% 1 year total shareholder return suggesting investors are steadily warming to Proto Labs growth and risk profile. If Proto Labs has you rethinking your watchlist, this is a good moment to...

Samsara Inc. recently reported its third-quarter 2026 results, with revenue rising to US$415.98 million and net income reaching US$7.77 million, marking its first quarter of GAAP profitability after a loss in the prior year period. The company paired this milestone with a 29% year-on-year increase in Annual Recurring Revenue, record additions of large enterprise customers, and growing international traction, underscored by customer case studies such as Swissport’s incident and vehicle damage...

Wondering if iQIYI at around $2 a share is a hidden bargain or a value trap? You are not alone, and this is exactly what we are going to unpack. The stock is roughly flat over the last week, down 8.1% over the past month and about 11% over the last year, after a brutal 88.2% slide over five years that still shapes how the market views its risk and recovery potential. Recent headlines have centered on iQIYI's ongoing push into premium originals and partnerships in China as it tries to...

If you are wondering whether Turning Point Brands is still a smart buy after its big run up, you are not alone. This article is going to unpack exactly what the current price might be baking in. The stock has climbed 6.0% over the last week, 4.1% over the last month, and is now up an eye catching 72.5% year to date, with a massive 430.9% gain over three years and 151.2% over five years that has clearly changed how the market views its prospects. Recent attention around Turning Point Brands...

Preformed Line Products (PLPC) just gave income focused investors something new to consider, approving a 5% hike to its quarterly dividend, the first increase since the company listed in 2001. See our latest analysis for Preformed Line Products. The move lands after a strong run, with the latest share price at $231.5 and an impressive year to date share price return of about 80%. The five year total shareholder return of roughly 267% shows that long term momentum has been firmly building. If...

Newell Brands (NWL) just paired a sweeping productivity overhaul, including more than 900 job cuts and 20 Yankee Candle store closures, with lowered Q4 guidance as Latin America sales improve more slowly than management expected. See our latest analysis for Newell Brands. Despite the sweeping restructuring moves, the share price has shown a 1 month share price return of about 18% and a 7 day share price return near 5%. However, that bounce sits against a much steeper year to date share price...

Navan (NAVN) has been under pressure lately, with the stock sliding about 19% over the past month and roughly 30% year to date. This has raised fresh questions about how investors should value its AI-driven travel platform. See our latest analysis for Navan. Zooming out, that sharp recent slide in Navan’s share price sits on top of an already weak year to date share price return. This suggests momentum has clearly cooled as investors reassess both growth runway and execution risk. If Navan’s...

Despite an already strong run, Arteris, Inc. ( NASDAQ:AIP ) shares have been powering on, with a gain of 27% in the...

Griffon (GFF) has quietly outperformed the broader market over the past week and month, and that steady climb is starting to draw attention from investors looking for durable industrial exposure. See our latest analysis for Griffon. The recent 1 month share price return of 7.88 percent, on top of a robust 3 year total shareholder return of 144.18 percent, suggests momentum is still firmly on Griffon’s side as investors reassess its growth and cash generation story. If Griffon’s run has you...

Wondering if Alnylam Pharmaceuticals at around $412 a share is still a smart buy after its huge run, or if the upside has already been priced in. The stock is down 11.3% over the last week and 8.7% over the past month, but even after that pullback it is still up 76.6% year to date and 68.2% over the last 12 months. Those moves have come as investors refocus on Alnylam's RNAi drug pipeline, major partnerships with big pharma, and the growing commercial traction of its approved therapies. The...